Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris-Reference-Cited by-同舟云学术

Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

Published:2019-02-03 Issue:6 Volume:30 Page:529-533
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Queille-Roussel C.¹,Nielsen J.²,Lacour J.-P.¹³

Affiliation:

1. Centre de Pharmacologie Clinique Appliquée à la Dermatologie, Nice, France;

2. LEO Pharma A/S, Ballerup, Denmark;

3. Service de Dermatologie, University Hospital of Nice, Nice, France

Funder

LEO Pharma Research Foundation

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://tandfonline.com/doi/pdf/10.1080/09546634.2018.1529385

Reference23 articles.

1. Psoriasis

2. Guidelines of care for the management of psoriasis and psoriatic arthritis

3. Assessment and management of psoriasis: summary of NICE guidance

4. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis

5. Method for Comparing Percutaneous Absorption of Steroids

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use;Dermatology Practical & Conceptual;2021-05-20

2. Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation;Expert Opinion on Pharmacotherapy;2021-03-22

3. Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-03

4. Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency;Journal of the European Academy of Dermatology and Venereology;2021-02

5. Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review;Advances in Dermatology and Allergology;2021